" class="no-js "lang="en-US"> Veritas and Jeffrey Modell Foundation Announce a Collaboration
Friday, March 31, 2023

Veritas and Jeffrey Modell Foundation Announce a Collaboration to Help Advance Early Diagnosis in Children with Primary Immunodeficiencies

The Jeffrey Modell Foundation (JMF) a global non-profit organization for Primary Immunodeficiency (PI) and Veritas, a letsgetchecked company, focused on genome and exome sequencing and their clinical interpretation, have announced a collaboration agreement to increase genomic diagnosis in the field of immunological disorders.

The agreement aims to identify PI gene defects to optimize precise diagnosis, disease management and appropriate treatment. The goal is to provide genetic sequencing services for children around the world who are suspected of having PI or other inborn errors of immunity.

“The diagnostic journey for patients with a PI is long and can take them to numerous pediatric specialists before a specific genetic diagnosis and treatment may be offered,” said MD, PhD Luis Izquierdo, Veritas’ Chief Medical Officer. “Genetic studies can contribute to the early diagnosis of PI , improving their prognosis and avoiding some of their most severe effects.”

Veritas’ genomics sequencing services will be offered as a sponsored service to the +900 physician members of the Jeffrey Modell Centers Network, across six continents. More than 200.000 patients with PID are being followed by the Jeffrey Modell Foundation.

“We are excited to begin our journey with Veritas to enhance our gene sequencing program and continue to give hope, improve the quality of life, and in some cases, cure children with PI worldwide,” said Vicki and Fred Modell, Co-Founders, Jeffrey Modell Foundation.

  1. Flare Therapeutics Further Strengthens Leadership Team with Key Executive Appointments and Promotions Read more
  2. Sensorion Appoints Khalil Barrage as Interim Chairman of the Board Read more
  3. Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China Read more
  4. Hansa Biopharma Completes Enrollment in Phase 2 Study of Imlifidase in Guillain-Barré Syndrome (GBS) Read more
  5. ProJenX Announces Formation of Scientific Advisory Board for Development of ALS Treatment Read more